BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Top Cited Papers
- 14 August 2014
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 26 (3), 428-442
- https://doi.org/10.1016/j.ccr.2014.07.006
Abstract
No abstract availableKeywords
Funding Information
- Huntsman Cancer Institute (P30 CA042014)
- NIH
- NCI (R01 CA178397)
- American Society of Hematology
- Leukemia & Lymphoma Society (5090-12)
- Howard Hughes Medical Institute
- NIH
- NCI MERIT award (R37CA065823)
- NIH (HL082978-01, 5 P01 CA049639-23, R01 CA178397)
- Leukemia & Lymphoma Society (LLS) Scholar in Clinical Research (7036-01)
- University of Utah Department of Medicinal Chemistry, a computing allocation at the XSEDE supercomputers (TG-CHE120086)
- Office of Science of the U.S. Department of Energy (DE-AC02-06CH11357)
This publication has 47 references indexed in Scilit:
- Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapyProceedings of the National Academy of Sciences of the United States of America, 2014
- Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDBlood, 2013
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationshipsBlood, 2013
- Ponatinib in Refractory Philadelphia Chromosome-Positive LeukemiasThe New England Journal of Medicine, 2012
- Pushing the limits of targeted therapy in chronic myeloid leukaemiaNature Reviews Cancer, 2012
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinibBlood, 2011
- The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance ProfileCancer Research, 2011
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Cancer Cell, 2011
- Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor ResistanceChemical Biology & Drug Design, 2010
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009